Ağır eozinofilik astımda anti-IL-5 tedaviler: gerçek yaşam verileri

Randomize kontrollü çalışmalar; anti-IL-5 tedavilerin eozinofilik ağır astımlıhastalarda oral kortikosteroid ihtiyacını, yıllık astım atak ve hastane yatış sayı-sını, kan eozinofil sayısını azalttığını; FEV1 değerlerini, astım kontrolünü veyaşam kalitesini arttırdığını göstermiştir. Anti-IL-5’lerin kullanıma girmesiylebirlikte gerçek yaşam çalışmaları yapılmaya başlanmıştır. Literatürde mepolizumab ile 10, benralizumab ve reslizumab ile yapılmış birer adet ilgili gerçekyaşam çalışması bulunmaktadır. Randomize kontrollü çalışmalara benzerşekilde gerçek yaşam çalışmalarında da mepolizumabın; oral kortikosteroidihtiyacını, yıllık astım atak ve atak nedenli hastaneye yatışları, kan eozinofilsayısını azalttığı; FEV1 değerlerini, astım kontrol testi skorlarını ve yaşam kalitesini arttırdığı bulunmuştur. Gerçek yaşam çalışmalarının bir kısmında yanıtlı-lık kriterleri belirlenmiş ve bu kriterlere göre yanıt oranları farklı olsa da ağıreozinofilik astımlı hastalarda anti-IL-5 tedavilerine yanıtların yüksek olduğugösterilmiştir. Anti-IL-5 tedavilerinin güvenirliliğinin değerlendirildiği gerçekyaşam çalışmalarında ise en sık yan etki, tedavi gerektirmeyen hafif lokalenjeksiyon yeri reaksiyonudur. Sonuç olarak şu ana kadar bildirilmiş gerçekyaşam çalışmaları kullanımda olan her üç anti-IL-5 tedavisinin etkili ve güvenli olduğunu göstermiştir.

Anti-IL-5 treatments in severe eosinophilic asthma: real life datas

Randomized controlled studies have shown that anti-IL-5 treatments reduce the need for oral corticosteroids, annual asthma exacerbation and hospitalization rates, blood eosinophil count and increase FEV1 values, asthma control, and quality of life in patients with eosinophilic severe asthma. Although the number of real-life studies with anti-IL-5 is limited, there are 10 real life studies with mepolizumab, one real life study with benralizumab and one real life study with reslizumab in the current literature. Similar to randomized controlled trials, real-life studies reported that a reduction in the need for oral corticosteroids, annual asthma exacerbation and hospitalization rates, and blood eosinophil counts and increase FEV1 values, asthma control test and quality of life scores, Response criteria were defined in some of the real-life studies and although different response rates were given according to these criteria, most of the patients with severe eosinophilic asthma showed high response rates to anti-IL-5 treatments. In real-life studies evaluating the safety of anti-IL-5 treatments, the most common adverse effect is mild local injection site reaction that does not require treatment, in conclusion, real-life studies suggest that all three anti-IL-5 treatments in clinical practice are effective and well tolerated.

Kaynakça

1. Menzella F, Bertolini F, Biava M, Galeone C, Scelfo C, Caminati M. Severe refractory asthma: current treatment options and ongoingresearch. Drugs Context 2018;7:212561.

2. Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet (London, England) 2008;372(9643):1107- 19.

3. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nature Med 2012;18(5):716- 25.

4. Fahy JV. Type 2 inflammation in asthma-present in most, absent in many. Nature re- views Immunology 2015;15(1):57-65.

5. Caminati M, Menzella F, Guidolin L, Senna G. Targeting eosinophils: severe asthma and beyond. Drugs in Context 2019;8:212587.

6. Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilicasthma. N Engl J Med 2014;371(13):1198-207.

7. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilicasthma (DREAM): a multicentre, double-blind, placebo-controlledtrial. Lancet 2012;380(9842):651–9.

8. Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014;371(13):1189–97.

9. Ortega HG, Yancey SW, Mayer B, Gunsoy NB, Keene ON, Bleecker ER, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thre sholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med 2016;4(7):549–56.

10. European Medicines Agency-European Public Assessment Report (EPAR) for Nucala (mepolizumab). https://www. ema.europa.eu/en/medicines/human/EPAR/nucala. Accessed March, 2019.

11. Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011;184(10):1125-32.

12. Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 2015;3(5):355-66.

13. Murphy K, Jacobs J, Bjermer L, Fahrenholz JM, Shalit Y, Garin M, et al. Long-term safety and efficacy of reslizumab in patients with eosinophilic asthma. J Allergy Clin Immunol Pract 2017;5(6):1572-81.e3.

14. US Food and Drug Administration. Reslizumab (Cinqair) prescribing information. http://www.cinqair.com/pdf/ PrescribingInformation.pdf (Accessed on March 28, 2016).

15. Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW, et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med 2014;2(11):879–90.

16. Fitz Gerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016;388(10056):2128-41.

17. Bleecker ER, Fitz Gerald JM, Chanez P, Papi A, Weinstein SF, Barker P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 2016;388(10056):2115–27.

18. Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, et al. Oral glucocorticoid-sparing effect of benralizumab in severeasthma. N Engl J Med 2017;376(25):2448-58.

19. Busse WW, Bleecker ER, Fitz Gerald JM, Ferguson GT, Barker P, Sproule S, et al. Long-termsafety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med 2019;7(1):46–59.

20. Drick N, Seeliger B, Welte T, Fuge J, Suhling H. Anti-IL-5 therapy in patients with severe eosinophilicasthma-clinical efficacy and possible criteria for treatment response. BMC Pulmonary Med 2018;18:119.

21. Pertzov B, Unterman A, Shtraichman O, Shitenberg D, Rosengarten D, Kramer MR. Efficacy and safety of mepolizumabin a real-world cohort of patients with severe eosinophilic asthma, J Asthma 2019;1658208.

22. Pelaia C, Busceti MT, Solinas S, Terracciano R, Pelaia G. Real-life evaluation of the clinical, functional, and hematological effects of T mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study. Pulmonary Pharmacology & Therapeutics 2018;53:1–5.

23. Numata T, Nakayama K, Utsumi H, Kobayashi K, Yanagisawa H, Hashimoto M, et al. Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis. BMC Pulmonary Medicine 2019;19:176.

24. Öztürk BÖ, Erdoğan BD, Eraslan D, Aydın Ö, Demirel Y, Mungan D ve ark. Eozinofilik ağır astımlı olgularda mepolizumab? Gerçek yaşam verileri. 26. Ulusal Alerji ve Klinik İmmünoloji Kongresi, Antalya, Türkiye 09-13 Kasım 2019.

25. Bagnasco D, Caminati M, Menzella F, Milanese M, Rolla G, Carlo Lombardi C, et al. One year of mepolizumab efficacy and safety in real-life in Italy. Pulmonary Pharmacology & Therapeutics 2019;58:101836.

26. Bagnasco D, Menzella F, Caminati M, Caruso C, Guida G, Bonavia M, et al. Efficacy of mepolizumab in patients with previous omalizumab treatment failure: Real life observation. Allergy 2019;00:1–3.

27. Harvey E, Langton DL, Powell H, Gibson PG. Clinical response to mepolizumab in patients with severe eosinophilic asthma. Eur Respir J 2019;54:PA541.

28. Harrison T, Canonica GW, Gemzoe K, Maxwell A, Yang S, Joksaite S, et al. Effectiveness and safety of mepolizumab in real-world clinical practice: the REALITI-A study. ERS International Congress, Madrid, Spain, 28 September-2 October 2019.

29. Taille C, Chanez P, Devouassoux G, Didier A, PisonC, Garcia G, et al. Real-life experience with mepolizumab in the French early access program for severe eosinophilic asthma. Eur Respir J 2019;54:PA1654.

30. Ibrahim H, O'Sullivan R, Casey D, Murphy J, MacSharry J, Plant BJ, et al. The effectiveness of reslizumab in severe asthma treatment: a real-world experience. Respir Res 2019;20(1):289.

31. Pelaia C, Busceti MT, Vatrella A, Rago GF, Crimi C, Terracciano R, et al. Real-life rapidity of benralizumab effects in patients with severe allergic T eosinophilic asthma: assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose. Pulmonary Pharmacology & Therapeutics 2019;58:101830.

Kaynak Göster